ArticleRadiation research2026
Enhanced Response to Radiopharmaceutical Therapy in Preclinical Tumor Models with XRD-0394, a Dual Inhibitor of ATM Kinase and DNA-PKcs.
Article in Radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Enhanced DNA repair is a common mechanism of radiation resistance. XRD-0394, a novel small molecule dual inhibitor of ataxia telangiectasia mutated (ATM) kinase and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PKcs), may sensitize tumor cells to killing by external beam radiation therapy (EBRT) or radiopharmaceutical therapy (RPT). DNA damage response inhibition and increased cytotoxicity were observed in Myc-CaP prostate cancer tumor cells after irradiation + XRD-0394 as indicated by the inhibition of radiation- induced phosphorylation of KAP1, p53, and H2A.X and decreased clonogenic potential. In mice bearing the FaDu head and neck squamous cell carcinoma (HNSCC) xenograft tumor model, the combination of irradiation or 177Lu-NM600 + XRD-0394 improved tumor response and overall survival compared to monotherapy controls. Increased expression of type I interferon response genes was observed after irradiation + XRD-0394 compared to irradiation alone, suggesting that XRD-0394 may also accentuate the immunogenic effects of radiation on tumor cells. Further investigation is warranted into treatment approaches that combine radiopharmaceutical therapies, DNA repair inhibitors, and immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.